ELAN vs. NVO: Elanco Animal Health vs. Novo Nordisk Stock Comparison

Company Profile

Elanco Animal Health (ELAN) and Novo Nordisk (NVO) are both classified in the Pharmaceuticals sub-industry within the broader Pharmaceuticals industry, placing them in the closest GICS peer bucket.

Elanco Animal Health (ELAN) trades as ordinary local shares, while Novo Nordisk (NVO) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Elanco Animal Health (ELAN) has an aggressive beta of 1.65, indicating higher sensitivity to broad-market moves, while Novo Nordisk (NVO) is defensive at 0.67 and tends to be less market-sensitive — they sit on opposite ends of the beta spectrum.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Capital efficiency shows on one side only: Novo Nordisk (NVO) earns 58.38% on shareholders’ equity, ranked against its industry; Elanco Animal Health (ELAN) has no ROE this period.

Elanco Animal Health (ELAN) reports a negative net margin of -2.86%, usually indicating a net loss over the period. Meanwhile Novo Nordisk (NVO) reports 33.92%, ranking against industry peers normally.

Novo Nordisk (NVO) at 40.05% operates in the top operating margin quartile, ahead of Elanco Animal Health (ELAN) at 6.64%, which runs around its industry’s norm.

Profitability Metrics

Growth

Both Elanco Animal Health (ELAN) at 6.22% and Novo Nordisk (NVO) at 6.43% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Novo Nordisk (NVO) at 1.77% is around its peer norm for EPS growth, while Elanco Animal Health (ELAN) at -169.12% drops into the bottom quartile, signaling weaker earnings momentum.

Growth Metrics

Financial Strength

Short-term liquidity can only be read on one side of this pairing: Novo Nordisk (NVO) shows current ratio of 0.85 against its industry benchmark, while Elanco Animal Health (ELAN) has no reading this period.

Both Elanco Animal Health (ELAN) at 0.64 and Novo Nordisk (NVO) at 0.62 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

Financial Strength Metrics

Dividends

Elanco Animal Health (ELAN) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Novo Nordisk (NVO) reports a yield of 29.03%, ranking against industry peers normally.

Elanco Animal Health (ELAN) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Novo Nordisk (NVO) reports a payout of 45.36%, ranking against industry peers normally.

Dividend Metrics

Valuation

An earnings multiple is available for just one side: Novo Nordisk (NVO) trades at 10.18 times trailing earnings, ranked against its peers, while Elanco Animal Health (ELAN) has no P/E ratio this period.

Both Elanco Animal Health (ELAN) at 2.50 and Novo Nordisk (NVO) at 0.53 fetch a relatively low price per dollar of sales, landing in the cheaper P/S ratio quartile of their industries.

On P/B ratio, both Elanco Animal Health (ELAN) at 1.95 and Novo Nordisk (NVO) at 5.43 are valued close to their industries’ norm against book — neither stands out from peers.

Valuation Metrics